Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 5/11/23 → 5/10/27 |
Financiación
- Merck Sharp & Dohme Corporation: 127.255,00 US$
22-HN-37-MSD (689-07): A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell
- Arnold, Susanne M (PI)